** Biotech firm Elicio Therapeutics' ELTX.O shares fall 14% to an over 2-month low of $6.71
** ELTX now expects mid-stage study data of its lead experimental vaccine, ELI-002, in Q3 2025 vs. previous expectation of H1 2025
** Co is testing vaccine against certain types of solid tumors that are caused by mutations in the KRAS gene, which are common in pancreatic, colorectal, and non-small cell lung cancers
** ELTX's net loss also widens in 2024 compared with 2023
** As of last close, ELTX has risen 2.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。